U.S. Stock Market Midday Update: Longevity Health down 7.07%

U.S. Stock Market Midday Update Longevity Health fell 7.07%, with increased trading volume. Based on recent important news: On July 29, HengRui Medicine had a block trade of 13.59 million shares at a 4% discount, raising market concerns about pharmaceutical stocks, leading to a decline in Longevity Health's stock price. On July 23, Junyao Health had a block trade at an 8.88% discount, which dampened market sentiment and affected related health stocks. On July 23, Meinian Health had a block trade at a 6.73% discount, further exacerbating negative sentiment in the health industry. Top Stocks by Industry Trading Volume Sarepta Therapeutics rose 18.54%, with a trading volume of $1.007 billion. Based on recent important news: On July 29, the FDA recommended lifting the pause on Sarepta's gene therapy Elevidys, causing the stock price to rise by 41.05%. On July 29, Barclays raised Sarepta's target price from $10 to $22, further boosting the stock price. On July 29, JP Morgan upgraded Sarepta's rating to neutral, considering the FDA's decision a clear victory. AbbVie rose 1.92%, with a trading volume of $724 million. Based on recent key news: On July 29, AbbVie submitted an FDA approval application for the combination treatment of VENCLEXTA® and Acalabrutinib for CLL, driving the stock price up. On July 29, Eli Lilly announced that its drug Jaypirca performed better in a head-to-head study against AbbVie's Imbruvica, undermining market confidence in AbbVie. On July 28, AbbVie's drugs Skyrizi and Rinvoq exceeded expectations, boosting investor confidence. Iklisys fell 16.34%, with increased trading volume. Based on recent important news: On July 29, Iklisys released its second-quarter financial report, with revenue falling short of expectations, leading to a 12% drop in stock price. On July 29, Morgan Stanley lowered Iklisys's target price from $48 to $46, further dampening market confidence. On July 29, the company announced the suspension of the STELLAR-305 Phase III trial and delayed the results of STELLAR-304, increasing market uncertainty. Top Stocks by Industry Market Capitalization Amgen rose 0.59%, with a market capitalization of $163 billion. Based on recent important news: On July 28, Amgen was included in the Dow Jones Dividend Stock List, highlighting its dividend attractiveness, which pushed the stock price up by 0.59% On July 29, analysts maintained a hold rating on Amgen, excluding it from the recommended list, limiting further price increases. On July 27, the overall market trading volume increased, with retail investors active, driving stock price fluctuations